Purine-scaffold Hsp90 inhibitors

IDrugs

Volumn 9, Issue 11, 2006, Pages 778-782

  Chiosis, Gabriela ^a   Tao, Hui ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer therapeutics; Heat shock protein 90; Hsp90; Purine scaffold

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IPI 504; PU 24FC 1; PU 3; PURINE; RADICICOL; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS, EXPERIMENTAL; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33751029714     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Chiosis G: Targeting chaperones in transformed systems - a focus on Hsp90 and cancer. Expert Opin Ther Targets (2006) 10(1):37-50.
2. Neckers L: Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handbook Exp Pharmacol (2006) (172):259-277.
3. Pacey S, Banerji U, Judson I, Workman P: Hsp90 inhibitors in the clinic. Handbook Exp Pharmacol (2006) (172):331-358.
4. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N: A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol (2001) 8(3):289-299.
5. Chiosis G, Huezo H, Lucas B, Rosen N: Development of a purine-based novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem (2002) 10(11):3555-3564.
6. Vilenchik M, Solit D, Basso A, Huezo, H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G: Targeting wide-range oncogenic transformation via PU24FCI, a specific Inhibitor of tumor Hsp90. Chain Biol (2004) 11(6):787-797.
7. Chiosis G: Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem (2006) 6(11):1183-1191.
8. Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A et al: Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem Biol (2004) 11(6):775-785.
9. Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang Y-C et al: Orally active purine-based inhibitors of the heat shock protein 90. J Med Chem (2006) 49(2):817-828.
10. He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G: Identification of potent water-soluble purine-scaffold Inhibitors of the heat shock protein 90. J Med Chem (2006) 49(1):381-390.